Malathy P Shekhar
Overview
Explore the profile of Malathy P Shekhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Q, Gajan A, Nguyen I, Sharma S, Nangia-Makker P, Firestine S, et al.
Pharm Res
. 2025 Feb;
PMID: 40021546
Purpose: Given its role in cancer development and progression, Rad6 is an underexplored therapeutic target. Previous research identified compound SMI#9 as a small molecule inhibitor of Rad6. Despite its potency,...
2.
Uddin M, Zhou J, Pimentel J, Patrick S, Kim S, Shekhar M, et al.
Front Oncol
. 2022 Jul;
12:908603.
PMID: 35847859
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable...
3.
Gajan A, Sarma A, Kim S, Gurdziel K, Wu G, Shekhar M
Front Oncol
. 2021 Aug;
11:694793.
PMID: 34367977
Poly-(ADP)-ribose polymerase inhibitors (PARPi) and platinum-based drugs are promising therapies for triple negative breast cancers (TNBC) with or loss. PARPi(s) show better efficacies when combined with platinum-based therapy, however, acquisition...
4.
Haynes B, Gajan A, Nangia-Makker P, Shekhar M
Biochim Biophys Acta Mol Basis Dis
. 2019 Oct;
1866(1):165561.
PMID: 31639439
Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with few therapy options besides chemotherapy. Although platinum-based drugs have shown initial activity in BRCA1-mutated TNBCs, chemoresistance remains a...
5.
Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, et al.
Mol Cancer Ther
. 2018 Sep;
17(12):2586-2597.
PMID: 30242094
The triple-negative breast cancer (TNBC) subtype, regardless of their BRCA1 status, has the poorest outcome compared with other breast cancer subtypes, and currently there are no approved targeted therapies for...
6.
Haynes B, Sarma A, Nangia-Makker P, Shekhar M
Cancer Metastasis Rev
. 2017 Jul;
36(3):547-555.
PMID: 28752247
Generation of intratumoral phenotypic and genetic heterogeneity has been attributed to clonal evolution and cancer stem cells that together give rise to a tumor with complex ecosystems. Each ecosystem contains...
7.
Sanders M, Haynes B, Nangia-Makker P, Polin L, Shekhar M
J Biol Chem
. 2017 May;
292(25):10347-10363.
PMID: 28490629
Platinum drug-induced cross-link repair requires the concerted activities of translesion synthesis (TLS), Fanconi anemia (FA), and homologous recombination repair pathways. The E2 ubiquitin-conjugating enzyme RAD6 is essential for TLS. Here,...
8.
Haagenson K, Tait L, Wang J, Shekhar M, Polin L, Chen W, et al.
Cancer Biol Ther
. 2012 Jul;
13(11):1042-6.
PMID: 22825334
Cullin-3 is a component of the Cullin-Ring ubiquitin ligase (CRL) family that plays an important role in mediating protein degradation. Deregulation of Cullin-3 expression has been observed in human cancers;...